97 results
6-K
RDHL
Redhill Biopharma Ltd.
24 Apr 24
Current report (foreign)
7:05am
being evaluated in the early treatment arm of the study. The primary efficacy assessment in the early treatment indication will be time to sustained
POS AM
RDHL
Redhill Biopharma Ltd.
18 Apr 24
Prospectus update (post-effective amendment)
7:00am
and Boone, LLP.
EXPERTS
The financial statements and management's assessment of the effectiveness of internal control over financial reporting
424B5
RDHL
Redhill Biopharma Ltd.
2 Apr 24
Prospectus supplement for primary offering
4:05pm
by Haynes and Boone, LLP.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial … upon for us by Haynes and Boone, LLP.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over
6-K
RDHL
Redhill Biopharma Ltd.
5 Mar 24
Current report (foreign)
7:01am
as a potential medical countermeasure (MCM) against inhalation Sulfur Mustard exposure. The overall evaluation will also include assessment of opaganib’s
424B5
xm4dkojm7cns54iu0
26 Jan 24
Prospectus supplement for primary offering
9:29am
6-K
8qkrjz1rklotde6
4 Dec 23
Current report (foreign)
7:03am
424B3
lk2fb beg
26 Oct 23
Prospectus supplement
4:52pm
F-3/A
eqqas ga1
23 Oct 23
Shelf registration (foreign) (amended)
4:06pm
F-3
3hvha18peg v72av
13 Oct 23
Shelf registration (foreign)
8:13am
424B3
6rx6jpuw20 k1c
11 Aug 23
Prospectus supplement
4:52pm
F-3
ahlm3erew7df
4 Aug 23
Shelf registration (foreign)
4:05pm
6-K
yk059j2k 9hzgmd9i
31 Jul 23
Current report (foreign)
7:03am
424B5
s636259lu
25 Jul 23
Prospectus supplement for primary offering
8:00am
424B5
n6csm g4w
3 Apr 23
Prospectus supplement for primary offering
8:49am
424B5
xo79tjs vzx
6 Dec 22
Prospectus supplement for primary offering
6:04am
6-K
EX-1.1
zzxb0l
5 Dec 22
Current report (foreign)
4:24pm
424B5
0rop bk7r505
2 Dec 22
Prospectus supplement for primary offering
6:31am